Compare Stocks → Incredible Opportunity to Retire FAST! (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BCDANASDAQ:ELEVNASDAQ:ONVONYSE:RCOR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$0.37+2.8%$0.42$0.32▼$2.92$9.67M1.47109,998 shs62,860 shsELEVElevation Oncology$4.05+6.6%$4.20$0.36▼$5.89$184.87M1.34865,537 shs485,444 shsONVOOrganovo$1.03-6.4%$1.04$0.89▼$2.05$11.04M0.912.93 million shs281,687 shsRCORRenovacor$3.20$3.07$1.34▼$9.74$55.26M-0.2830,033 shsN/A10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia+2.17%-1.24%-10.07%-21.43%-81.70%ELEVElevation Oncology+6.58%-8.58%-10.00%+56.98%+121.31%ONVOOrganovo-6.36%-23.70%+0.98%+0.98%-49.75%RCORRenovacor0.00%0.00%0.00%0.00%0.00%Incredible Opportunity to Retire FAST! (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCDABioCardia2.7995 of 5 stars3.35.00.00.02.23.30.0ELEVElevation Oncology2.7483 of 5 stars3.52.00.00.03.92.50.6ONVOOrganovoN/AN/AN/AN/AN/AN/AN/AN/ARCORRenovacorN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCDABioCardia2.50Moderate Buy$4.00987.55% UpsideELEVElevation Oncology3.00Buy$7.2579.01% UpsideONVOOrganovoN/AN/AN/AN/ARCORRenovacorN/AN/AN/AN/ACurrent Analyst RatingsLatest ONVO, ELEV, RCOR, and BCDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2024ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/7/2024ELEVElevation OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$7.003/7/2024ELEVElevation OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$5.00 ➝ $8.003/7/2024ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/1/2024ELEVElevation OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$7.002/20/2024ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.50 ➝ $6.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCDABioCardia$480K20.59N/AN/A($0.07) per share-5.25ELEVElevation OncologyN/AN/AN/AN/A$1.29 per shareN/AONVOOrganovo$370K27.95N/AN/A$1.76 per share0.59RCORRenovacorN/AN/AN/AN/A$2.47 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCDABioCardia-$11.57M-$0.55N/AN/AN/A-2,425.79%-3,638.68%-228.55%5/8/2024 (Estimated)ELEVElevation Oncology-$45.70M-$1.53N/AN/AN/AN/A-72.76%-43.15%5/20/2024 (Estimated)ONVOOrganovo-$17.26M-$2.17N/AN/AN/AN/A-182.88%-138.52%7/11/2024 (Estimated)RCORRenovacor-$14.10M-$0.73N/AN/AN/AN/A-62.88%-48.90%N/ALatest ONVO, ELEV, RCOR, and BCDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023BCDABioCardia-$0.11-$0.09+$0.02-$0.09$0.20 million$0.01 million3/6/2024Q4 2023ELEVElevation Oncology-$0.21-$0.19+$0.02-$0.19N/AN/A2/8/2024Q3 2024ONVOOrganovo-$0.41-$0.40+$0.01-$0.40$0.08 million$0.01 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCDABioCardiaN/AN/AN/AN/AN/AELEVElevation OncologyN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/ARCORRenovacorN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCDABioCardiaN/A0.400.40ELEVElevation Oncology0.5521.2221.22ONVOOrganovoN/A3.673.67RCORRenovacorN/A6.606.60OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCDABioCardia20.57%ELEVElevation Oncology83.70%ONVOOrganovo8.23%RCORRenovacor45.84%Insider OwnershipCompanyInsider OwnershipBCDABioCardia23.90%ELEVElevation Oncology14.90%ONVOOrganovo5.00%RCORRenovacor14.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBCDABioCardia1626.87 million20.45 millionOptionableELEVElevation Oncology2948.65 million41.40 millionOptionableONVOOrganovo1810.04 million9.54 millionOptionableRCORRenovacor1917.27 million14.78 millionNot OptionableONVO, ELEV, RCOR, and BCDA HeadlinesSourceHeadlineRecord Store Day 2024: How to Flatten Warped Vinyl Records at Homecnet.com - April 22 at 7:23 PMThe best record players 2024: Top turntables for any budgettomsguide.com - April 20 at 3:40 PMBest turntables 2024: Bluetooth record players for Record Store Daystuff.tv - April 20 at 10:39 AMNews of Recordnewsandsentinel.com - March 30 at 4:05 AMNHL opening night delivers record viewership on ESPNnhl.com - November 6 at 5:27 PMState Pension payments worth over £2,000 each month for older people living in these European countriesdailyrecord.co.uk - October 30 at 1:55 PMThe best early Black Friday turntable deals 2023whathifi.com - October 29 at 12:00 AMAnas Sarwar 'unhappy' with Keir Starmer over Labour leader's response to Gaza crisisdailyrecord.co.uk - October 27 at 2:36 PMNYC shoplifting hit record highs last year: ‘We can’t stop them’nypost.com - October 24 at 1:35 PMTranscriptional control of the inflammatory responsenature.com - October 18 at 7:59 AMRockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directorsfinance.yahoo.com - October 17 at 7:56 AMFolwell criticizes fellow Republicans on public records rollbackwral.com - October 14 at 8:16 PMBest Bluetooth turntables 2023: wireless record players for streaming vinylwhathifi.com - October 11 at 12:09 PMHere’s why you shouldn’t record meltdowns on an airplane: FAA insidernypost.com - October 3 at 11:57 PMRecord-breaking heat wave peaking in Eastern U.S. with highs near 100washingtonpost.com - September 28 at 6:28 PMiOS 17: How to Record a FaceTime Video or Audio Messagemacrumors.com - September 15 at 7:16 PMThis was the world’s hottest summer on record ‘by a large margin’washingtonpost.com - September 9 at 6:12 PMCapCut breaths life into new-wave blogging for modern businessesdailyrecord.co.uk - September 6 at 9:28 AMMontauk trailer listing eyes record — even with a price cuttherealdeal.com - September 5 at 11:26 PMRecord-Breaking Summer: Portland, New Orleans Break Daily High Temperature Records After Hottest July Everforbes.com - August 23 at 10:13 AMRecord-Breaking Summer: Jacksonville, Miami Break Daily High Temperature Records, After Hottest July Everforbes.com - August 16 at 6:56 PMPhoenix, New Orleans, Baton Rouge Break Daily High Temperature Records: Here’s Where Else Daily Records Have Fallenforbes.com - August 11 at 7:09 PMPhoenix, Dallas, Little Rock Break Daily High Temperature Records: Here’s Where Else Daily Records Have Fallenforbes.com - August 9 at 12:55 AMPhoenix just posted the hottest month ever observed in a U.S. citywashingtonpost.com - August 5 at 9:27 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideArm Holdings Stock Elevating on AI, Cloud, Automotive TailwindsMarch 26, 2024 9:05 AMView Arm Holdings Stock Elevating on AI, Cloud, Automotive TailwindsAll Headlines Company DescriptionsBioCardiaNASDAQ:BCDABioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.Elevation OncologyNASDAQ:ELEVElevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.OrganovoNASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.RenovacorNYSE:RCORRenovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.